Xenon Pharmaceuticals (XENE) reported a Q4 net loss late Tuesday of $0.84 per diluted share, widening from a loss of $0.64 a year earlier.

Analysts polled by FactSet expected a loss of $0.88.

No revenue was recorded in the three months ended Dec. 31, as expected.

The company had $754.4 million in cash, cash equivalents and marketable securities at the end of December and expects to have sufficient liquidity to fund operations into 2027.